← Back to Clinical Trials
Recruiting NCT04767568

NCT04767568 Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04767568
Status Recruiting
Phase —
Sponsor Centre Hospitalier Universitaire de Besancon
Condition Colorectal Cancer
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2021-03-30
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Blood sampleTumor tissuestool collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2021-03-30 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Colorectal cancer (CRC) is the third most common cancer in men and the second in women with an incidence of 43,350 new cases in 2018. This incidence is increasing every year. Early detection is crucial in this pathology. In France, free screening is organized by health insurance for people aged 50 to 74 years. This screening is based on an immunological test (FIT: Fecal Immunological test), which aims to detect the presence of blood in the stool. In fact, some polyps or cancers cause bleeding that is often minimal and therefore difficult or even impossible to detect with the naked eye. If this test is positive, a colonoscopy is done to check whether or not abnormalities are present in the colon or rectum. Performed under anesthesia, this examination can detect the possible presence of polyps or cancer. Recently, with the covid-19 epidemic, the investigators were faced with an extension of the delays for colonoscopies which led to delays in patient care. To prevent this, they propose to develop a blood test that would allow rapid identification of patients with colorectal cancer, requiring rapid management. This blood test will permit to have a parameter for stratifying the therapeutic care in the event of epidemia or situation that constrains the organisation of the health system.

Eligibility Criteria

Inclusion Criteria: * Patients aged more than18 years * Cohort A : patients with suspected colorectal cancer following a positive immunological test during screening (presence of blood detected in the stool) or with gross bleeding OR Cohort B : patients who have already performed colonoscopy (on symptoms, or because of family history, or other ...), for whom the diagnosis of adenocarcinoma was identified by pathology prior to surgery, candidates for surgery on their colorectal tumor * Signed and dated informed consent * Patient affiliated to or beneficiary of French social security system. Exclusion Criteria: * Vulnerable persons according to the law (minors, adults under protection, persons deprived of liberty ...) * Not ability to comply with the study protocol, in the Investigator's judgment * pregnant woman * Patient in the period of exclusion of another study

Contact & Investigator

Central Contact

Christophe BORG, Pr

✉ christophe.borg@efs.sante.fr

📞 +33381668166

Frequently Asked Questions

Who can join the NCT04767568 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04767568 currently recruiting?

Yes, NCT04767568 is actively recruiting participants. Contact the research team at christophe.borg@efs.sante.fr for enrollment information.

Where is the NCT04767568 trial being conducted?

This trial is being conducted at Besançon, France, Montbéliard, France, Vesoul, France.

Who is sponsoring the NCT04767568 clinical trial?

NCT04767568 is sponsored by Centre Hospitalier Universitaire de Besancon. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology